About HemoCue
HemoCue is a company based in Angelholm (Sweden) founded in 1982 was acquired by Radiometer in February 2013. HemoCue offers products and services including HemoCue Hb 201 DM System, HemoCue Glucose 201 + System, HemoCue HbA1c 501 System, and HemoCue WBC DIFF System. HemoCue operates in a competitive market with competitors including SD Biosensor, EzeRx, Biosense, TrueHb and Cercacor, among others.
- Headquarter Angelholm, Sweden
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hemocue Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
EQT
& 1 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HemoCue
HemoCue offers a comprehensive portfolio of products and services, including HemoCue Hb 201 DM System, HemoCue Glucose 201 + System, HemoCue HbA1c 501 System, and HemoCue WBC DIFF System.
Device for point-of-care hemoglobin analysis in clinical settings
System for monitoring glucose levels at point-of-care
Tool for HbA1c screening and diabetes management
System for white blood cell differential analysis
People of HemoCue
Unlock access to complete
Funding Insights of HemoCue
Detailed funding history for HemoCue
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in HemoCue
HemoCue has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include EQT and Radiometer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Radiometer is recognized as a leader in acute care diagnostics.
|
Locked | Locked | Locked |
Investor details for HemoCue
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HemoCue
Investment portfolio details for HemoCue
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HemoCue
Detailed financials for HemoCue
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemocue Comparisons
Peer comparison for HemoCue
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HemoCue
HemoCue operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, EzeRx, Biosense, TrueHb and Cercacor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| Locked | Locked | Locked |
Non-invasive IoT diagnostic devices are manufactured for accessible health screening.
|
|
| Locked | Locked | Locked |
Diagnostic devices for multiple diseases are developed and provided.
|
|
| Locked | Locked | Locked |
Portable hemoglobin measurement devices are manufactured for at-home testing.
|
|
| Locked | Locked | Locked |
Non-invasive hemoglobin monitoring devices are developed for athletes.
|
|
| Locked | Locked | Locked |
Finger-prick point-of-care diagnostics are provided for biomarker testing.
|
Detailed competitors of HemoCue
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemocue
Complete news archive for HemoCue
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HemoCue
HemoCue was founded in 1982.
HemoCue is headquartered in Angelholm, Sweden.
Christophe Duret is the current CEO of HemoCue.
HemoCue was founded in 1982 in Ängelholm, Sweden, where point-of-care diagnostic tests are developed, manufactured, and distributed for hematology and diabetes monitoring. Instruments and disposable microcuvettes are provided for measuring hemoglobin, glucose, urine albumin, HbA1c, and white blood cell counts in various samples. The company was acquired by Quest Diagnostics in 2007 for approximately 420 million, integrating its operations into broader clinical diagnostics services.
HemoCue's top competitors include SD Biosensor, Nova Biomedical and Biosense.
HemoCue offers HemoCue Hb 201 DM System, HemoCue Glucose 201 + System, HemoCue HbA1c 501 System, and HemoCue WBC DIFF System.
HemoCue has 2 investors. Key investors include EQT, and Radiometer.